cripgbm

cRIPGBM, a proapoptotic derivative of RIPGBM, selectively induces apoptosis in GBM cancer stem cells (CSCs) by targeting receptor-interacting protein kinase 2 (RIPK2), demonstrating an EC50 of 68 nM in GBM-1 cells [1].

cRIPGBM chloride is an orally active, proapoptotic compound derived from glioblastoma multiforme (GBM) cancer stem cells (CSCs). It specifically targets receptor-interacting protein kinase 2 (RIPK2) to trigger caspase 1-dependent apoptosis. By inhibiting the formation of the RIPK2/TAK1 prosurvival complex and promoting the assembly of the RIPK2/caspase 1 proapoptotic complex, cRIPGBM chloride efficiently suppresses tumor growth. This action results in significant anti-tumor activity in animal models in vivo.